Eli Lilly and Company (LLY)
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide. The company's latest approval strengthens its diabetes portfolio.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock
Lilly's largest shareholder just filed to unload nearly $350 million in stock while analysts keep raising their price targets, and those two facts point in opposite directions for investors trying to read the room.
Eli Lilly (LLY) Just Overtook the 50-Day Moving Average
Eli Lilly (LLY) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, LLY broke through the 50-day moving average, which suggests a short-term bullish trend.
Lilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound
Eli Lilly's two blockbuster drug approvals that transformed the company into a pharmaceutical giant turned out to be the worst moments to buy the stock.
Eli Lilly: Dominance Has A Price
Eli Lilly remains a compelling diversification play, especially for portfolios with significant AI exposure. LLY trades at approximately 24x FY2027 EPS estimates, reflecting its premium status without appearing expensive. I maintain a Strong Buy rating on LLY, confident in its long-term bullish thesis and potential to outperform the S&P 500.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.26% move from the prior day.
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
The 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,359.12 over the next 12 months. With the stock at $1,142.85, that implies 18.92% upside.
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
